Ongoing Clinical Trials for Large Cell Lung Cancer Recurrent
There are currently 3 clinical trials investigating new treatments and diagnostic approaches for recurrent large cell lung cancer. These studies are taking place across several European countries and are exploring immunotherapy combinations, innovative diagnostic tests, and personalized cell therapies to improve outcomes for patients with this aggressive form of lung cancer.
Clinical trial locations
- Czechia
- France
- Germany
- Hungary
- Spain
Study on Atezolizumab, Carboplatin, and Etoposide for Adults with Advanced Large-Cell Neuroendocrine Lung Cancer
This trial is testing a combination of immunotherapy and chemotherapy for patients with large-cell neuroendocrine carcinoma, a particularly aggressive type of lung cancer. The study combines atezolizumab, an immunotherapy that helps the immune system fight cancer, with standard chemotherapy drugs carboplatin (or cisplatin) and etoposide. All medications are given through intravenous infusion directly into the bloodstream.
Who can participate: Adults aged 18 or older with locally advanced or metastatic large-cell neuroendocrine lung cancer that cannot be cured with surgery. Participants must not have received previous systemic therapy, though those who had curative treatment that ended at least 6 months before the cancer returned may be eligible. Patients should be able to perform daily activities reasonably well, with an ECOG performance status of 0 to 2. The cancer must be measurable according to standard criteria, and participants must have adequate organ function, including appropriate levels of liver enzymes, bilirubin, creatinine, neutrophils, and platelets.
Who cannot participate: Patients who received other cancer treatments within the last 4 weeks, those with severe allergies to the study drugs, active infections requiring treatment, or other serious medical conditions that could interfere with the study. Pregnant or breastfeeding women, those who participated in another trial within 4 weeks, and patients with a history of another cancer (unless in remission for at least 5 years) are excluded. Patients with untreated or unstable brain metastases, uncontrolled autoimmune diseases, or a history of recent drug or alcohol abuse also cannot participate.
Study focus: The main goal is to evaluate how well this treatment combination works in improving survival and how the cancer responds to therapy. Researchers will monitor changes in tumor size, how long it takes for the cancer to start growing again, and overall survival. The study will also carefully track any side effects patients experience from the treatment.
Study on the Accuracy of OWL-EVO1 Test for Diagnosing Lung Cancer in Patients Eligible for Screening or with Suspicious CT Findings
This trial is investigating a novel diagnostic approach called the OWL-EVO1 Breath Biopsy test, which aims to improve the accuracy of lung cancer diagnosis. The test uses a special solution called D5-ethyl-beta-D-glucuronide given through intravenous infusion, followed by breath sample collection and analysis.
Who can participate: Adults between 45 and 85 years old who can understand and consent to the study. Participants must have a body mass index (BMI) between 16 and less than 40 and must have received a CT scan of the chest area within the last 6 months. This study is designed for people undergoing lung cancer screening or those with CT scan findings suspicious for lung cancer.
Who cannot participate: Individuals who are not eligible for lung cancer screening based on low-dose CT scans, those without suspicious findings on their CT scan, and individuals whose symptoms are not consistent with a possible lung cancer diagnosis.
Study focus: The primary aim is to assess how accurately the OWL-EVO1 test can identify lung cancer compared to traditional diagnostic methods. The test analyzes breath samples collected at various time points to detect specific markers that may indicate cancer. The study will also monitor the safety and tolerability of the test, ensuring it poses minimal risk to participants. This research could lead to earlier and more accurate lung cancer detection.
Study on the Safety and Effects of ATL001 and Pembrolizumab in Adults with Advanced Non-Small Cell Lung Cancer
This trial explores a personalized treatment approach combining ATL001, an innovative cell therapy using specially designed immune cells (T cells), with pembrolizumab, an established immunotherapy drug. The study examines how these treatments work both individually and together in fighting advanced non-small cell lung cancer.
Who can participate: Patients between 18 and 75 years old with a life expectancy of at least 6 months. Participants must have advanced non-small cell lung cancer that cannot be surgically removed or has spread to other parts of the body, and the cancer must have worsened after standard treatments or the patient cannot tolerate standard treatments. The disease must be measurable according to medical guidelines, and patients should be in reasonably good health with an ECOG performance status of 0-1. Importantly, patients must have previously received a PD-1/PD-L1 inhibitor medication with either disease progression or stable disease after at least four doses. The cancer must be smoking-related, and patients must have accessible tumor sites for tissue collection. Adequate organ function is required, and women of childbearing potential must agree to use effective contraception during treatment and for at least 12 months afterward.
Who cannot participate: Patients with other types of cancer besides non-small cell lung cancer, those unable to follow study procedures, and individuals with medical conditions or taking medications that might interfere with the study. Pregnant or breastfeeding women, those who recently participated in another clinical trial, and patients with a history of allergic reactions to the study drugs are excluded.
Study focus: The main goal is to assess the safety and tolerability of ATL001 as a treatment. The study involves collecting tumor tissue to manufacture the personalized ATL001 therapy, preparing the body through lymphodepletion (using fludarabine and cyclophosphamide), administering ATL001 through infusion, and in some cases combining it with pembrolizumab. Researchers will monitor how tumors respond to treatment, track changes in tumor size, and measure overall health outcomes, including how long patients live without their cancer worsening. Regular follow-up assessments will continue through the estimated study conclusion in July 2027.
Summary
The three ongoing clinical trials for recurrent large cell lung cancer demonstrate a multifaceted approach to improving patient outcomes. Germany is involved in two of the three trials, suggesting a concentration of research activity in this country. The trials span multiple European nations including France, Spain, Hungary, and Czechia, providing patients across the region with access to cutting-edge research.
The studies represent three distinct approaches to addressing this challenging disease: combination immunotherapy with chemotherapy, novel diagnostic testing, and personalized cell therapy. Two trials focus on immunotherapy agents, with atezolizumab and pembrolizumab being investigated in combination with other treatments. This reflects the growing importance of immunotherapy in lung cancer treatment.
Notably, one trial focuses exclusively on improving diagnosis rather than treatment, highlighting the critical need for better diagnostic tools to detect lung cancer earlier and more accurately. The personalized approach using ATL001 represents the most experimental treatment option, targeting patients who have already received standard therapies.
Patient eligibility varies significantly across trials, with age ranges from 18 to 85 years and different requirements regarding previous treatments. This diversity ensures that patients at various stages of their cancer journey may find an appropriate trial option.
